SCHEMBL5607007

SCHEMBL5607007

Cc1ccccc1C(=O)Nc1ccc(C[C@H](N)C(=O)O)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 2/20 0.65
HPGD P15428 1/20 0.61
SMN1; SMN2 Q16637 5/20 0.61
ALPI P09923 1/20 0.54
PKM P14618 1/20 0.54
PTGS1 P23219 1/20 0.54
XIAP P98170 1/20 0.54
SLC7A5 Q01650 1/20 0.54
NPC1 O15118 4/20 0.53
RAB9A P51151 4/20 0.53
MAPT P10636 3/20 0.53
THRB P10828 1/20 0.53
TYK2 P29597 1/20 0.52
ALDH1A1 P00352 4/20 0.52
GAA P10253 3/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
ITGB3 P05106 1/20 0.52
ITGAV P06756 1/20 0.52
ITGA2B P08514 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5607021 1.00 FFAR1 (0.65) FFAR1HPGDSMN1; SMN2ALPIPKM
SCHEMBL5607148 0.84 SMO (0.70) SMN1; SMN2ALPIPKMPTGS1XIAP
SCHEMBL5078480 0.84 SMO (0.70) SMN1; SMN2ALPIPKMPTGS1XIAP
SCHEMBL5607183 0.84 MAPK1 (0.59) HPGDSMN1; SMN2ALPIPKMPTGS1
SCHEMBL5607190 0.84 MAPK1 (0.59) HPGDSMN1; SMN2ALPIPKMPTGS1
SCHEMBL5607808 0.84 MAPT (0.60) SMN1; SMN2NPC1RAB9AMAPTALDH1A1
SCHEMBL5607803 0.84 MAPT (0.60) SMN1; SMN2NPC1RAB9AMAPTALDH1A1
SCHEMBL757263 0.82 ITGB3 (0.67) SMN1; SMN2ALPIPKMPTGS1XIAP
SCHEMBL7769029 0.82 ITGB3 (0.67) SMN1; SMN2ALPIPKMPTGS1XIAP
SCHEMBL19234470 0.82 ITGB3 (0.67) SMN1; SMN2ALPIPKMPTGS1XIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US claimed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US disclosed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US disclosed
WO-2007082264-A2 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS GLP1R, GIPR, IAPP FFAR1 88/4885HPGD 2659/4885SMN1; SMN2 1582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.